NEWS
Melbourn Scientific to announce faster formulation at ICSE
ICSE 2010
Hall 4, Stand 4F110
A new fast formulation screening service, that will accelerate the
development of formulations where poor bioavailability is an issue, is to be announced by Melbourn Scientific at ICSE.
The service includes investment in a new platform technology that will allow analysts to rapidly evaluate a wide range of formulations.
This extension to its formulation capability, which includes Good
Manufacturing Practice (GMP) of capsules for early phase clinical trials, is
focussed on making drug and device development programmes faster and more productive.
Mark Hammond, CEO for Melbourn Scientific, a leading provider of product
development support, says that in the early stages the concept of
'fit-for-purpose' is paramount to an efficient transition from lead
optimisation to first-in-man studies.
"An experienced partner will ensure that the formulation and testing
procedures reflect the adequate requirements for a pre-clinical or
first-in-man trial whilst making certain that sufficient data is collated
for regulatory purposes at each stage. This will help the product get to
clinic in a cost effective and time efficient manner."
The partnership approach Melbourn Scientific adopts with its clients has
proven very successful in fast-tracking molecules at various stages from
lead to launch. The company has one of the largest teams of analysts,
formulators and product development experts in Europe.
"Our clients are at the forefront of innovation and some also want to have a hands-on approach. We offer them the opportunity to work alongside our scientists at our facilities in dedicated project rooms that protects their confidentiality and that of our other clients."
Other facilities include a formulation suite with lab-scale manufacture,
support for novel device development, and extended stability storage and test rooms.